Iradimed Begin Period Cash Flow from 2010 to 2024
| IRMD Stock | USD 54.21 0.14 0.26% |
Begin Period Cash Flow | First Reported 2013-03-31 | Previous Quarter 45.1 M | Current Value 48.5 M | Quarterly Volatility 19.2 M |
Check Iradimed financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Iradimed's main balance sheet or income statement drivers, such as Interest Expense of 702.6 K, Selling General Administrative of 9.3 M or Selling And Marketing Expenses of 7.8 M, as well as many indicators such as Price To Sales Ratio of 9.61, Dividend Yield of 0.0316 or PTB Ratio of 10.29. Iradimed financial statements analysis is a perfect complement when working with Iradimed Valuation or Volatility modules.
Iradimed | Begin Period Cash Flow |
Latest Iradimed's Begin Period Cash Flow Growth Pattern
Below is the plot of the Begin Period Cash Flow of Iradimed Co over the last few years. It is the amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities. Iradimed's Begin Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Iradimed's overall financial position and show how it may be relating to other accounts over time.
| Begin Period Cash Flow | 10 Years Trend |
|
Begin Period Cash Flow |
| Timeline |
Iradimed Begin Period Cash Flow Regression Statistics
| Arithmetic Mean | 24,871,823 | |
| Geometric Mean | 9,752,247 | |
| Coefficient Of Variation | 95.70 | |
| Mean Deviation | 20,422,211 | |
| Median | 18,205,976 | |
| Standard Deviation | 23,801,158 | |
| Sample Variance | 566.5T | |
| Range | 61.4M | |
| R-Value | 0.96 | |
| Mean Square Error | 51.7T | |
| R-Squared | 0.92 | |
| Slope | 5,091,548 | |
| Total Sum of Squares | 7930.9T |
Iradimed Begin Period Cash Flow History
About Iradimed Financial Statements
Iradimed stakeholders use historical fundamental indicators, such as Iradimed's Begin Period Cash Flow, to determine how well the company is positioned to perform in the future. Although Iradimed investors may analyze each financial statement separately, they are all interrelated. For example, changes in Iradimed's assets and liabilities are reflected in the revenues and expenses on Iradimed's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Iradimed Co. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Begin Period Cash Flow | 58 M | 60.9 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Iradimed is a strong investment it is important to analyze Iradimed's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Iradimed's future performance. For an informed investment choice regarding Iradimed Stock, refer to the following important reports:Check out the analysis of Iradimed Correlation against competitors. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Iradimed. If investors know Iradimed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Iradimed listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0) | Dividend Share 0.45 | Earnings Share 1.46 | Revenue Per Share 5.635 | Quarterly Revenue Growth 0.11 |
The market value of Iradimed is measured differently than its book value, which is the value of Iradimed that is recorded on the company's balance sheet. Investors also form their own opinion of Iradimed's value that differs from its market value or its book value, called intrinsic value, which is Iradimed's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Iradimed's market value can be influenced by many factors that don't directly affect Iradimed's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Iradimed's value and its price as these two are different measures arrived at by different means. Investors typically determine if Iradimed is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Iradimed's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.